@AASLDtweets take away message #2 from #LIverMtg18 is that #hcv elimination starts with offering one stop shopping including #harmreduction, addiction and antiviral treatment. Will plan to implement in our practice
0
0
0
0
Hashtag
#livermtg18
Advertisement · 728 × 90
@AASLDtweets my take away messages from #livermtg18: thyroid receptor beta agonists and drugs acting via FGF-19 are promising for NASH but risk/benefit far from established
0
0
0
0
thanks to the tireless @AASLDtweets staff who make it all happen! Also very excited about @AASLDFoundation #TomorrowsCures campaign launched at #LiverMtg18 . Let’s all help cure liver disease by investing in funding meritorious research
0
0
0
0
@AASLDtweets @EASLnews @EASLedu Well it’s a wrap for #LiverMtg18 on my end. Already looking forward to next year as well as #ilc2019 in Vienna from April 10-14
0
0
0
0
@AASLDtweets dr chalasani: chronic liver disease may be a risk factor of DILI but by no means clear. Increased exposure with advanced liver disease seems to matter #livermtg18
0
0
0
0
@AASLDtweets HY’s law: AST or ALT > 3x ULN (or baseline) plus total bilirubin > 2x ULN (or baseline) without cholestasis or competing etiology. Carries 10-15% mortality and is the graveyard of many drugs in development #livermtg18
0
0
0
0
@AASLDtweets dr chalasani cites paritaprevir, grazoprevir and obethiclolic acid as associated with DILI in some pts with advanced liver disease due to increased exposure. I would argue that in most of these cases, this is true/true and unrelated #livermtg18
0
0
0
0
@AASLDtweets statin hepatotoxicity not more likely to happen in chronic liver disease. Do not withold beneficial statins just because someone has elevated ALT eg: fatty liver #LiverMtg18
0
0
0
0
@AASLDtweets are persons with chronic liver disease more likely to have DILI and does it end up being more severe? Dr chalasani @IUMedSchool reviews #LiverMtg18
0
0
0
0
congrats to @dibiscam for a well deserved @AASLDtweets distinguished service award. Might also be the first liver Twitterati to garner such a prestigious award! #LiverMtg18
0
0
0
0
@AASLDtweets The idea that we can eliminate #HCV in the US without treating PWIDs is a myth. It’s time to put our implicit biases aside and push payers to grant med access to PWIDs #livermtg18
0
0
0
0
@AASLDtweets data like the ANCHOR study further confirm that cure of even the most marginalized of #HCV infected persons is possible today #LiverMtg18
0
0
0
0
@AASLDtweets dr rosenthal: ANCHOR study shows that even poorly adherent PWIDs still achieves an 89% #HCV cure rate #harmreduction #hcvelimination #LiverMtg18
0
0
0
0
@AASLDtweets dr finn: CELESTIAL trial of #cabozantinib is the only ph3 study to enroll patients who had undergone 2 lines of therapy including IO drugs #LiverMtg18
0
0
0
0
@AASLDtweets as survival with systemic therapies approaches or exceeds 3 years, one has to wonder whether locoregional therapy has any role in most pts with intermediate and advanced #HCC #Livermtg18
0
0
0
0
@AASLDtweets dr. Al khoueiri @USC #sorafenib experienced #HCC patient overall survival with #opdivo was 15 months vs. 29 months for sorafenib naive patients! We’ve come a long way from a decade ago #livermtg18
0
0
0
0
@AASLDtweets dr Heimbach: resection not a good idea after radiation therapy for cholangiocarcinoma due to tissue damage creating issues with anastomoses #livermtg18
0
0
0
0
@AASLDtweets Dr. Heimbach highlights recent data which show an unacceptable 56% graft loss in patients treated with immuno-oncology drugs. JUST DON’T DO IT! #livermtg18
0
0
0
0
@AASLDtweets Dr. Heimbach: also coming in 2019: HCC patients will no longer accrue points over time but rather have a fixed score which is the Mean MELD at transplant for the region minus 3 #livermtg18
0
0
0
0
@AASLDtweets Dr. Heimbach: #HCC Cap and 6 month delay strategy has evened out transplant rates for cancer and non cancer. Good or bad? You decide #livermtg18
0
0
0
0
@AASLDtweets Dr. Heimbach highlights the stunning fact that liver cancer is the second leading cause of cancer death worldwide. A call for action #livermtg18
0
0
0
0
@AASLDtweets Dr. Julie Heimbach @MayoClinic delivers the #LiverMtg18 Starzl lecture on the management of hepatobiliary cancers in Hall D
0
0
0
0
@AASLDtweets one consequence of having a case based PGC this year is that presenters have allowed themselves to share their own practice in controversial areas where evidence is scarce. #LiverMtg18
0
0
0
0
@AASLDtweets dr Mangus: it’s very hard to get a liver/intestine transplant #LiverMtg18
0
0
0
0
@AASLDtweets dr sweet: in a nutshell, it’s really hard to get a combined liver/lung transplant #livermtg18
0
0
0
0
@AASLDtweets The #livermtg18 theme of the meeting for me so far is “ex-vivo perfusion”. Something I know very little about.
0
0
0
0
@AASLDtweets interestingly there is some consensus on the panel to only do secondary SBP prophylaxis in most patients Esp. since norfloxacin not currently available in US #livermtg18
0
0
0
0
@AASLDtweets Dr Garcia-Tsao: in a patient with cr >1.2, na <130, bili >3 or CPT >9 aka child C or circulatory dysfunction no difference in infection and no survival benefit #livermtg18
0
0
0
0
@AASLDtweets my practice has been not to offer SBP prophylaxis to child c cirrhosis and those with circulatory dysfunction based on these data but the issue remains controversial #LiverMTG18
0
0
0
0
@AASLDtweets In a patient with low ascites protein <1 antibiotic prophylaxis results in less infection but no survival benefit #livermtg18
0
0
0
0